NASDAQ:AFMD
Affimed N.V. Stock News
$5.35
+0.350 (+7.00%)
At Close: Apr 23, 2024
Affimed to Present at Upcoming Investor Conferences
06:30am, Wednesday, 04'th Nov 2020
Heidelberg, Germany, November 4, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced
Affimed to Report 3rd Quarter 2020 Financial Results & Corporate Update November 10, 2020
06:30am, Tuesday, 03'rd Nov 2020
Heidelberg, Germany, November 3, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today
Billionaire Steven Cohen Pulls the Trigger on These 3 Penny Stocks
07:30pm, Monday, 17'th Aug 2020
There are two sides to every coin. For penny stocks, or tickers that trade for less than $5 per share, this rings especially true. As some of the most divisive names on the Street, they are either met
Affimed N.V. (AFMD) Q2 2020 Earnings Call Transcript
11:31pm, Tuesday, 11'th Aug 2020
On the call today we are joined by doctors Adi Hoess, our Chief Executive Officer; Andreas Harstrick, Chief Medical Officer; Arndt Schottelius, Chief Scientific Officer; and Angus Smith, our new Chief
Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates
11:55am, Tuesday, 11'th Aug 2020
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -50.00% and -52.45%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Affimed: Q2 Earnings Insights
11:29am, Tuesday, 11'th Aug 2020
Shares of Affimed (NASDAQ:AFMD) moved higher by 4% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 5.26% over the past year to ($0.18), which miss
Affimed Reports Second Quarter 2020 Financial Results and Operational Progress
10:30am, Tuesday, 11'th Aug 2020
* Continued progress in the AFM13 pTCL REDIRECT monotherapy study * AFM24 is recruiting patients in cohort 2 of a Phase 1/2a clinical trial * Genentech’s RO7297089 is actively recruiting patients
Earnings Outlook For Affimed
02:57pm, Monday, 10'th Aug 2020
Affimed (NASDAQ: AFMD) releases its next round of earnings this Tuesday, August 11. Here's Benzinga's essential guide to Affimed's Q2 earnings report.Earnings and Revenue Affimed EPS will likely be ne
Affimed Announces Two New Appointments to Its Supervisory Board
10:30am, Wednesday, 05'th Aug 2020
Heidelberg, Germany, August 5, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced t
Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020
10:30am, Tuesday, 04'th Aug 2020
Heidelberg, Germany, August 4, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today th
Introducing Affimed (NASDAQ:AFMD), A Stock That Climbed 76% In The Last Three Years
12:23pm, Friday, 31'st Jul 2020
Affimed N.V. (NASDAQ:AFMD) shareholders might be concerned after seeing the share price drop 22% in the last month...
Affimed N.V. (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
04:33pm, Wednesday, 29'th Jul 2020
Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Affimed's Innate Immune Programs Offer A Compelling Value At Current Price Levels
11:12am, Friday, 24'th Jul 2020Affimed Announces Annual General Meeting of Shareholders
10:30am, Friday, 10'th Jul 2020
Heidelberg, Germany, July 10, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight.
Affimed: Updates To Thesis, Time To Gain Exposure To Innate Immuno-Oncology
12:58pm, Wednesday, 01'st Jul 2020
Shares have risen by 145% since my initial recommendation and by 65% since my October update. In ROTY's model account, our full-size, maximum-weighted position
